Navigation Links
KineMed to Collaborate With Merck KgaA to Validate New Applications for Drug Development Candidates

Technology to be Applied to Both Clinical- and Preclinical-Stage Compounds

in Merck KGaA Pipeline

EMERYVILLE, Calif., Aug. 28 /PRNewswire/ -- KineMed, Inc., a pathway-based drug discovery and development company, announced today that it will collaborate with Merck Serono, a division of Merck KGaA, Darmstadt, Germany, to discover new applications for drug candidates. KineMed's proprietary pathway-based drug discovery and development technology identifies compounds that can modulate key metabolic pathways present in both preclinical animal models and in humans. By measuring real-time activity of drugs against these targeted pathways, KineMed's technology reduces development risk by selecting drug candidates with the best potential to demonstrate clinical efficacy and confirm desired drug activity in first-in-man studies.

In the collaboration, KineMed will identify new therapeutic utility in in vivo preclinical models by applying its proprietary translational medicine technologies. Once a disease target is established for a selected drug candidate, KineMed and Merck KGaA will jointly determine the best development and commercialization path for the development candidates being studied.

Under the terms of the agreement, KineMed will receive from Merck an upfront payment, milestones and royalty payments on products advanced with KineMed's technology. Additional terms of the deal were not disclosed.

David Fineman, President and CEO of KineMed, commented, "We are pleased to expand our relationship with Merck KGaA into this broader development collaboration. Our technology uniquely enables our partners to screen development candidates against KineMed's dynamic targets of pathway kinetics. Partnering with KineMed further enables its partners to rapidly demonstrate on-mechanism dose response in first-in-man studies with KineMed's unique translational medicine capabilities."

Mr. Fineman continued, "In this collaboration with Merck, KineMed will be using its technology to identify new therapeutic activities of pipeline compounds. The collaboration preserves KineMed's freedom to operate on its own development programs as well as partner with other companies in key disease indications."

About KineMed, Inc.

KineMed, Inc. ("KineMed" or the "Company") is a drug discovery and development company employing its proprietary translational medicine technology (AquaTag(TM) and KineMarker(TM)) to both identify active drug candidates preclinically and confirm their therapeutic activity and dose response in first-in-man studies. KineMed's technology expedites the drug development process and provides real-time insight into conditions including metabolic disorders, cancer, and diseases of inflammation and neurodegeneration.

KineMed is working to develop drugs both on its own and with pharmaceutical collaborators in therapeutic focus areas where it can demonstrate functional modulation of specific biological pathways that mediate disease. The Company has multiple development programs with more than a dozen major pharmaceutical companies, including Bayer, Merck, Merck KGaA, Organon and Roche.

For further information about KineMed, please visit:

SOURCE KineMed, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. GE, St. Jude to collaborate on visualization technology
2. GE Healthcare, MobileAccess to collaborate on hospital wireless
3. GE Healthcare, Harvard medical school to collaborate on nervous system research
4. Madison, Milwaukee med schools to collaborate on tech transfer
5. EraGen collaborates with Emory University on HIV detection system
6. Sequence-Validated and Expression-Tested Human cDNA in a Dual Expression Vector
7. Silencer Validated siRNAs
8. Using Validated siRNAs in Functional Genomic Assays
9. YOUR DATA: Direct Real-time RT-PCR on Sympathetic Neuron Lysates Silencing of Focal Adhesion Kinases with Silencer Validated siRNAs
10. YOUR DATA: Direct Real-time RT-PCR on Sympathetic Neuron Lysates Silencing of Focal Adhesion Kinases with Silencer Validated siRNAs
11. Stem cell bank announcement validates quality of Wisconsin research
Post Your Comments:
(Date:11/26/2015)... , England , November 26, 2015 /PRNewswire/ ... Medical, an innovative medical device company specializing in imaging technologies, ... from the European Commission as part of the Horizon 2020 ... company to carry out a large-scale clinical trial in breast ...      (Logo: , --> ...
(Date:11/25/2015)... , Nov. 25, 2015  PharmAthene, Inc. (NYSE ... has adopted a stockholder rights plan (Rights Plan) in ... operating loss carryforwards (NOLs) under Section 382 of the ... --> PharmAthene,s use of its NOLs could ... change" as defined in Section 382 of the Code. ...
(Date:11/25/2015)... -- Studies reveal the differences in species ... the way for more effective treatment for one of the ... --> --> Gum disease ... cats, yet relatively little was understood about the bacteria associated ... conducted by researchers from the WALTHAM Centre for Pet Nutrition ...
(Date:11/25/2015)... DIEGO , Nov. 25, 2015  Neurocrine Biosciences, ... Kevin Gorman , President and CEO of Neurocrine Biosciences, ... Healthcare Conference in New York . ... to visit the website approximately 5 minutes prior to ... A replay of the presentation will be available on ...
Breaking Biology Technology:
(Date:11/18/2015)... , November 18, 2015 ... has published a new market report titled  Gesture Recognition ... and Forecast, 2015 - 2021. According to the report, the global ... and is anticipated to reach US$29.1 bn by 2021, ... North America dominated the ...
(Date:11/16/2015)... Nov 16, 2015  Synaptics Inc. (NASDAQ: ... solutions, today announced expansion of its TDDI product ... touch controller and display driver integration (TDDI) solutions ... These new TDDI products add to the previously-announced ... TD4302 (WQHD resolution), and TD4322 (FHD resolution) solutions. ...
(Date:11/10/2015)... LONDON , Nov. 10, 2015 /PRNewswire/ ... segmented on the basis of product, type, ... segments included in this report are consumables, ... this report are safety biomarkers, efficacy biomarkers, ... in this report are diagnostics development, drug ...
Breaking Biology News(10 mins):